Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

doi:10.3324/haematol.2021.278645

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

Haematologica - 1 Apr 2022

Kayser Sabine, Kramer Michael, Martínez-Cuadrón David, Grenet Justin, Metzeler Klaus H, Sustkova Zuzana, Luskin Marlise R, Brunner Andrew M, Elliott Michelle A, Gil Cristina, Marini Sandra Casal, Ráčil Zdeněk, Cetkovsky Petr, Novak Jan, Perl Alexander E, Platzbecker Uwe, Stölzel Friedrich, Ho Anthony D, Thiede Christian, Stone Richard M, Röllig Christoph, Montesinos Pau, Schlenk Richard F, Levis Mark J

Abstract excerpt

The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBFAML) in an international, multicenter survey of 97 patients of whom 52% had t(8;21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53 years (range, 19-81). Complete remission after anthracycline-based induction (n=86) and non-intensive therapy (n=11)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factors

Share to fms-Like Tyrosine Kinase 3

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Prognosis

Share to Remission Induction

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 34348451
DOI: 10.3324/haematol.2021.278645
PMCID: PMC8968900

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.PMID 34348451Read ↗

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupSemantic proximity Read ↗

Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐upSemantic proximity Read ↗

KIT and FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric Core-Binding Factor Acute Myeloid Leukemia: Findings from the C-HUANAN-AML-15 Multicenter Cohort StudySemantic proximity Read ↗

Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor-Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.Semantic proximity Read ↗

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.Semantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients.Semantic proximity Read ↗

Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation.Semantic proximity Read ↗

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.